Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith S Kaye

Showing results (271-280 of 421) with videos related to

Pageof 43
Sort By:
Antimicrobial Agents and Chemotherapy|April 24, 2004
Variety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United StatesKeith S Kaye, Howard S Gold, Mitchell J Schwaber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 9, 2017
Electronically Available Comorbidities Should Be Used in Surgical Site Infection Risk AdjustmentSarah S Jackson, Surbhi Leekha, Laurence S Magder, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2020
Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial InfectionsKeith S Kaye, Helen W Boucher, Michelle L Brown, et al.
Infection Control and Hospital Epidemiology|March 8, 2014
Risk factors for colonization due to carbapenem-resistant Enterobacteriaceae among patients exposed to long-term acute care and acute care facilitiesAshish Bhargava, Kayoko Hayakawa, Ethan Silverman, et al.
American Journal of Infection Control|May 20, 2014
Outcomes of carbapenem-resistant Enterobacteriaceae isolation: matched analysisChristopher Bogan, Keith S Kaye, Teena Chopra, et al.
Infection Control and Hospital Epidemiology|July 1, 2010
Observer bias in hand hygiene compliance reportingSorabh Dhar, Ryan Tansek, Elizabeth A Toftey, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 3, 2025
Corrigendum to "A quasi-experimental study of a bundled diagnostic stewardship intervention for ventilator-associated pneumonia" [Clin Microbiol Infect 30 (2024) 499-506]Owen R Albin, Jonathan P Troost, Louis Saravolatz, et al.
Antibiotics (Basel, Switzerland)|August 6, 2021
In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant <i>Acinetobacter baumannii</i>Jacinda C Abdul-Mutakabbir, Juwon Yim, Logan Nguyen, et al.
Infection Control and Hospital Epidemiology|July 5, 2012
Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory testsDror Marchaim, Bharath Sunkara, Paul R Lephart, et al.
Annals of Clinical Microbiology and Antimicrobials|June 5, 2015
Simple bedside score to optimize the time and the decision to initiate appropriate therapy for carbapenem-resistant EnterobacteriaceaeViolet Leibman, Emily T Martin, Ruthy Tal-Jasper, et al.
Pageof 43

Showing results (271-280 of 421) with videos related to

Sort By:
Pageof 43
Antimicrobial Agents and Chemotherapy|April 24, 2004
Variety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United StatesKeith S Kaye, Howard S Gold, Mitchell J Schwaber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 9, 2017
Electronically Available Comorbidities Should Be Used in Surgical Site Infection Risk AdjustmentSarah S Jackson, Surbhi Leekha, Laurence S Magder, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2020
Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial InfectionsKeith S Kaye, Helen W Boucher, Michelle L Brown, et al.
Infection Control and Hospital Epidemiology|March 8, 2014
Risk factors for colonization due to carbapenem-resistant Enterobacteriaceae among patients exposed to long-term acute care and acute care facilitiesAshish Bhargava, Kayoko Hayakawa, Ethan Silverman, et al.
American Journal of Infection Control|May 20, 2014
Outcomes of carbapenem-resistant Enterobacteriaceae isolation: matched analysisChristopher Bogan, Keith S Kaye, Teena Chopra, et al.
Infection Control and Hospital Epidemiology|July 1, 2010
Observer bias in hand hygiene compliance reportingSorabh Dhar, Ryan Tansek, Elizabeth A Toftey, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 3, 2025
Corrigendum to "A quasi-experimental study of a bundled diagnostic stewardship intervention for ventilator-associated pneumonia" [Clin Microbiol Infect 30 (2024) 499-506]Owen R Albin, Jonathan P Troost, Louis Saravolatz, et al.
Antibiotics (Basel, Switzerland)|August 6, 2021
In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant <i>Acinetobacter baumannii</i>Jacinda C Abdul-Mutakabbir, Juwon Yim, Logan Nguyen, et al.
Infection Control and Hospital Epidemiology|July 5, 2012
Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory testsDror Marchaim, Bharath Sunkara, Paul R Lephart, et al.
Annals of Clinical Microbiology and Antimicrobials|June 5, 2015
Simple bedside score to optimize the time and the decision to initiate appropriate therapy for carbapenem-resistant EnterobacteriaceaeViolet Leibman, Emily T Martin, Ruthy Tal-Jasper, et al.
Pageof 43